Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

1.75
-0.0300-1.69%
Post-market: 1.770.0195+1.11%19:59 EDT
Volume:4.18M
Turnover:7.39M
Market Cap:65.49M
PE:-1.19
High:1.84
Open:1.81
Low:1.73
Close:1.78
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:0.46
T/O Rate:23.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.58
PE(LYR):-1.30

Loading ...

Company Profile

Company Name:
Tenax Therapeutics
Exchange:
NASDAQ
Establishment Date:
1967
Employees:
15
Office Location:
101 Glen Lennox Drive,Suite 300,Chapel Hill,North Carolina,United States
Zip Code:
27517
Fax:
- -
Introduction:
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Directors

Name
Position
Christopher T. Giordano
President and Chief Executive Officer and Director
Gerald T. Proehl
Director and Chairman
Stuart Rich
Chief Medical Officer and Director
Declan Doogan
Director
June Almenoff
Director
Michael Davidson
Director
Robyn M. Hunter
Director

Shareholders

Name
Position
Christopher T. Giordano
President and Chief Executive Officer and Director
Thomas A. McGauley
Interim Chief Financial Officer
Stuart Rich
Chief Medical Officer and Director